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Acute-on-chronic liver failure 
Hepatic encephalopathy 
A B S T R A C T   
Liposome-supported peritoneal dialysis (LSPD) with transmembrane pH-gradient liposomes was previously 
shown to enhance ammonia removal in cirrhotic rats and holds promise for the treatment of hyperammonemic 
crises-associated disorders. The main objective of this work was to conduct the preclinical evaluation of LSPD in 
terms of pharmacokinetics, ammonia uptake, and toxicology to seek regulatory approval for a first-in-human 
study. The formulation containing citric acid-loaded liposomes was administered intraperitoneally at two dif-
ferent doses once daily for ten days to healthy minipigs. It was also tested in a domestic pig model of hyper-
ammonemia. The pharmacokinetics of citric acid and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine was linear 
following intraperitoneal administration of medium and high dose. There was no systemic accumulation fol-
lowing daily doses over ten days. The systemic exposure to phospholipids remained low. Furthermore, the 
liposome-containing peritoneal fluid contained significantly higher ammonia levels than the liposome-free 
control, demonstrating efficient ammonia sequestration in the peritoneal space. This was indeed confirmed by 
the ability of LSPD to decrease plasmatic ammonia levels in artificially induced hyperammonemic pigs. LSPD 
was well tolerated, and no complement activation-related pseudoallergy reactions were observed. The safety 
profile, the linear pharmacokinetics of citric acid following repeated administrations of LSPD as well as the linear 
dose-dependent ammonia sequestration in the peritoneal space provide a strong basis for the clinical in-
vestigation of LSPD.   
1. Introduction 
Ammonia is a highly abundant metabolite implied in amino acid 
metabolism, protein degradation, and acid-base homeostasis [1]. As 
ammonia is neurotoxic, the urea cycle has evolved to control its sys-
temic levels, acting as an efficient metabolic pathway in the liver [1]. 
Toxic increases in systemic ammonia levels mainly stem from inherited 
or acquired impairments in hepatic ammonia detoxification [1]. In 
hereditary hyperammonemia, one or several enzymatic defects due to 
inborn errors of metabolism hinder the detoxification capacity of the 
urea cycle (deficiencies in urea cycle enzymes and transporters, organic 
acidemias) [2,3], whereas acquired hyperammonemia is secondary to a 
liver injury (liver failure, hepatitis, drug-induced hepatotoxicity, 
cirrhosis). Sustained elevated blood ammonia leads acute or chronic 
neurotoxicity resulting in adult patients in a severe neuropsychiatric 
disorder called hepatic encephalopathy (HE). Symptoms range from 
subtle cognitive impairment to altered mental status, hepatic coma and 
death [4]. Hyperammonemic crisis (HAC) associated to HE is a sig-
nificant contributor of morbidity and often requires critical care man-
agement in the intensive care unit [4]. The mechanisms by which 
ammonia leads to irreversible cerebral damages involve dysregulated 
amino acid pathways and neurotransmitter systems, as well as cerebral 
energy metabolism, nitric oxide synthesis and oxidative stress [5]. 
As severe and prolonged HAC is associated with a poor prognosis, 
rapid detoxification measures aiming at lowering ammonia levels are 
crucial to reduce the risks of irreversible cognitive damage, long-term 
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sequelae and death [6–8]. Ammonia scavengers such as sodium phe-
nylbutyrate or the carbamoyl phosphate 1 stimulating agent carglumic 
acid are indicated for the long term treatment of inborn errors of me-
tabolism affecting the urea cycle [2,9–11]. HAC are managed with 
hemofiltration or hemodialysis; however, due to the difficulty in es-
tablishing vascular access lines in neonates and the lack of appropriate 
equipment, pediatric patients must be transferred to highly specialized 
tertiary centers where this intervention is often initiated too late [12]. 
Current practice guidelines for the treatment of HE in adults with an 
underlying liver injury recommend the administration of the non-ab-
sorbable disaccharide lactulose, a laxative with pH-lowering and pre-
biotic effects, and the minimally absorbed antibiotic rifaximin, which 
target the microbial production of ammonia in the gut [4]. Lactulose 
and rifaximin are mostly effective for the maintenance therapy in 
chronic HE to reduce the recurrence of HAC but their clinical benefit for 
severe cases remains controversial [4]. Therefore, the development of 
novel treatments for early and effective management of HAC is war-
ranted. 
Recently, a novel approach for treating hyperammonemic patients 
was reported [13]. It was found that micrometer-sized transmembrane 
pH-gradient liposomes bearing an acidic core and administered via the 
peritoneal route sequestered ammonia in the peritoneal cavity (Fig. 1) 
and significantly attenuated brain edema in a rat model of secondary 
biliary cirrhosis [13,14]. The transmembrane pH-gradient allowed for a 
strong and efficient sequestration of ammonia while passively clearing 
other clinically relevant liver and uremic toxins [15,16]. Furthermore, 
the large size of the liposomes restricted their systemic bioavailability 
upon peritoneal administration [13,14,17]. The present study mainly 
aimed at characterizing in minipigs the toxicokinetics, ammonia uptake, 
and toxicology of two doses (medium and high) of peritoneally applied 
transmembrane pH-gradient liposomes, which were previously shown to 
display good efficacy in rats [13] in view of the first-in-human (FIH) 
clinical trial. This animal model was chosen due to its high sensitivity to 
colloids potentially leading to complement activation-related pseu-
doallergy (CARPA), which exceeds the reaction observed in humans 
[18]. A secondary objective of this study was to confirm ammonia cap-
ture in an artificially-induced hyperammonemic domestic pig model. 
2. Materials and methods 
2.1. Materials 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl- 
sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] 
(mPEG-DSPE) were supplied by Corden Pharma Switzerland LLC (Liestal, 
Switzerland) or Lipoid GmbH (Ludwigshafen, Germany). Cholesterol (Chol) 
was purchased from Carbogen Amcis B.V. (Veenendaal, The Netherlands) or 
Sigma Aldrich (Buchs, Switzerland). Heparin was obtained from LEO 
Pharma (5000 IU/mL, Copenhagen, Denmark). Triton X100 and all other 
chemicals were purchased from Sigma Aldrich (St. Louis, MO). Physioneal® 
35 Glucose was obtained from Baxter (Søborg, Denmark). 
2.2. Methods and animal studies 
2.2.1. Preparation of peritoneal dialysis fluids 
For the repeated dose toxicity study, the liposome-supported peri-
toneal dialysis (LSPD) formulation was supplied as a 3-bottle kit each 
containing a citric acid solution, a liposomal aqueous suspension and a 
xylitol alkaline solution. The liposomal aqueous suspension was pre-
pared according to a protocol which was developed for the scale-up 
production. Appropriate amount of water for injection was heated up to 
60 °C in a jacketed stainless-steel vessel. A lyophilized lipid blend of 
DPPC:Chol:mPEG-DSPE (85.5:14:0.5 mol%) was then added into the 
vessel under mild stirring to reach a final lipid concentration of 
100 mg/mL. After 2 h, the suspension was degassed prior to filling and 
was steam sterilized according to the Ph. Eur. guidelines (9th Edition, 
Chapter 5.1.1) (≥121 °C, ≥15 min). The citric acid (115 mg/mL, 
pH 2.0) and xylitol alkaline (21.3 mg/mL, pH 12.3) solutions were 0.2- 
μm filtered and steam sterilized using similar conditions. 
For the ammonia infusion study, the liposomal aqueous suspension 
was prepared by lipid film hydration method as previously described 
[13]. Briefly, the lipid mixture of DPPC, Chol, and mPEG-DSPE was 
dissolved at 85.5:14:0.5 mol% in CH2Cl2/MeOH (95:5, v/v). The lipid 
film was formed upon solvents evaporation in a rotary evaporator (KNF 
Neuberger, Freiburg, Germany) and kept under vacuum overnight. The 
film was then rehydrated with ultrapure water for 1 h at 56 °C, and the 
liposomal suspension (100 mM lipids) was degassed under vacuum, 
purged with argon, and sterilized by autoclaving for 20 min at 120 °C 
(Varioklav, H + P Labortechnik AG, Oberschleissheim, Germany). 
DPPC and Chol concentrations were quantified by high-performance 
liquid chromatography equipped with a charged aerosol detector 
(Dionex UltiMate® 3000, Thermo Scientific, Sunnyvale, CA) as pre-
viously described [13] and the amount of endotoxins by a commercial 
pyrogen test kit (Endosafe®-PTS™, Charles River Laboratories, Ger-
many). The citric acid (pH 2, 1050 mOsm kg−1, 600 mM) and xylitol 
alkaline (pH 12.4, 415 mOsm kg−1, 135 mM) solutions were prepared 
as previously reported [15], vacuumed-filtered (0.22 μm, TPP® Fil-
termax, Sigma Aldrich), autoclaved (20 min, 120 °C), and their en-
dotoxin content quantified. The osmolality of each solution was verified 
(Osmomat 3000 basic freezing point osmometer, Gonotec GmbH, 
Berlin, Germany). 
Immediately before use, the transmembrane pH gradient was gen-
erated via an osmotic shock as described previously [13,15]. Briefly, the 
citric acid solution was added to the liposome solution and gently 
agitated for at least 15 min. The acidic suspension was then added to 
the xylitol alkaline solution and gently mixed. The resulting suspension 
was left at room temperature for at least 10 min; the final pH (between 
5 and 8) and visual aspect (milky) were controlled before use. The 
control solution Physioneal® 35 was reconstituted as per the manufac-
turer's instructions and infused within 24 h after mixing. 
2.2.2. Animals 
All the experiments conducted as part of the repeated dose tox-
icology study of LSPD were carried out in Göttingen minipigs. These 
Fig. 1. Schematic depiction of peritoneal ammonia capture using transmem-
brane pH-gradient liposomes. The unprotonated form of ammonia readily dif-
fuses across the liposomal bilayer. Upon entering the acidic liposomal lumen, it 
is protonated and subsequently trapped in the core due to its positive charge. 
Applied as a peritoneal dialysis solution, these liposomes can extract ammonia 
from the body. 
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experiments were conducted in accordance with Executive Order No. 
1245 of December 12th 2005 on Good Laboratory Practice (GLP) for 
Medicinal Products as required by the Danish Medicinal Agency and in 
compliance with OECD Principles of GLP. The study, which was carried 
out by Citoxlab Scantox A/S (Lille Skensved, Denmark), was performed 
in 23 minipigs (12 males and 11 females; Ellegaard Göttingen Minipigs 
A/S, Dalmose, Denmark) in a GLP facility. At arrival, the animals were 
approximately 3 to 4 months old and their body weight was between 
6.7 and 9.5 kg for males and 7.4 to 10.7 kg for females. A pre-treatment 
period of at least 20 days was allowed including an acclimatization 
period of 5 days to the dosing set-up (e.g., jackets, tubing). The animals 
were fed in the morning prior to dosing and in the afternoon. They had 
ad libitum access to domestic quality drinking water. 
The non-clinical proof of concept study in a large animal model was 
performed in domestic pigs (Sus scrofa domesticus) at the University of 
Zurich (Tierspital, Vetsuisse Faculty, Zurich, Switzerland) in ac-
cordance with procedures and protocols approved by the cantonal ve-
terinary authorities (protocol number of the license ZH159/15 26846) 
(see Section 2.2.8). The animals were acclimated for 7 days before the 
experiments, observed daily to ensure healthy status, and fasted over-
night prior to anesthesia. 
2.2.3. Surgical procedure and placement of catheter 
At least one week before the repeated treatment initiation in 
Göttingen minipigs, catheters were aseptically implanted in the animals 
under general anesthesia with 40 mg azaperone/mL (0.05 mL/kg) and 
1 mg atropine/mL (0.05 mL/kg) given as a single intramuscular in-
jection, followed by an intramuscular injection in the neck of a mixture 
of Zoletil 50® Vet., Virbac, France (0.1 mL/kg body weight). In addi-
tion, the animals were given a subcutaneous injection of 5 mg melox-
icam/mL (0.08 mL/kg) on the day of surgery and once daily for the 
following two days. Amoxicillin 150 mg/mL (0.1 mL/kg) was ad-
ministered as an intramuscular injection on the day of operation and 
once daily for the following six days. 
Incision into the peritoneal cavity was performed in the caudal flank 
of the animals. The coiled catheter (Covidien Peritoneal Prepritonl Cuf 
Kt, Medtronic Denmark, Copenhagen, Denmark) was introduced 
through the incision and placed as far caudo-ventrally as possible to 
avoid being trapped by the omentum and to facilitate the evacuation of 
dialysate at the end of the peritoneal dialysis (PD) session. The catheter 
was tunneled subcutaneously and exited the skin dorso-laterally. The 
patency of the catheter was then tested by infusing and retrieving 
sterile warm saline solution. Finally, a heparin lock of 5 mL heparin 
(5 IU/mL) was infused. After closing the wound, the incision site was 
covered with bandage and a protective jacket was put on animals to 
minimize infections. For treatment of post-surgical pain, the animals 
were given a transdermal patch of fentanyl (25 μg/h) for three days. 
2.2.4. Treatment regimen 
Prior to commencement of repeated treatments, Göttingen minipigs 
were allocated to the LSPD group or the control group (Physioneal® 35 
Glucose 1.36% w/v) according to Table 1. Dialysis sessions were per-
formed daily for 10 days until the day before necropsy for the main 
study animals; a treatment free period of at least 14 days was added for 
the recovery animals. A volume of 30 mL/kg of the liposomal or control 
PD fluid was infused over a period of 20 min through the implanted 
intraperitoneal catheter using peristaltic pumps. After a dwell time of 
3 h  ±  20 min, the dialysate was recovered by gravity while the ani-
mals were restrained. Collection was continued until at least 75% of the 
test item had been retrieved or for a maximum of 10 min. Following 
collection, a heparin lock of 3 mL was infused into the catheter and the 
volume of dialysate recovered was measured. 
2.2.5. Pharmacokinetics 
2.2.5.1. Blood, LSPD and dialysate samples. On days 1 and 10, blood 
samples were taken from all Göttingen minipigs at the following 
timepoints: pre-treatment and 0.5, 1, 2, 3, 5, 7, 12, 16 and 24 h post- 
dose. On day 10, an additional blood sample was collected 48 h after 
start of treatment. Blood samples of approximately 3 mL were drawn 
from the jugular vein/bijugular trunk into vacutainers containing 
potassium ethylenediaminetetraacetate (EDTA) as anticoagulant. The 
vacutainer was placed in ice water until centrifugation (10 min, 1270 x 
g, 4 °C). Plasma samples were transferred to Nunc cryotubes 
(polypropylene tubes with internal thread, Thermo Scientific, 
Denmark) and then frozen at −70 °C or below within 1 h after 
collection pending analysis. 
On the first (day 1) and last days of treatment (day 10), two samples 
of 3 mL were collected from the LSPD fluid (test item) before admin-
istration (time 0 h). In addition, two samples were collected from the 
dialysate in Nunc cryotubes at 1, 2 and 3 h  ±  5 min after the initiation 
of treatment and were immediately placed in ice water. The test item 
and dialysate samples were stored frozen at −70 °C or below within 1 h 
after collection pending analysis of citric acid, DPPC and cholesterol. 
Citric acid, DPPC and cholesterol concentrations in plasma, in LSPD 
and in the dialysate were determined by Atlanbio (Saint Nazaire, 
France) in compliance with the GLP regulations. Validated bioanaly-
tical method were based on protein precipitation followed by liquid 
chromatography with tandem mass spectrometry (LC-MS-MS). The 
sampling volume was of 10 μL. Each run included 8 non-zero calibra-
tion standards extracted in duplicate from the lower limit of quantita-
tion (LLOQ) to the upper limit (UL) and two Quality Controls (QC) at 
each QC level. Calibration curve and QCs' nominal concentrations for 
each method are presented in the supporting information (SI) section. 
The LC-MS/MS analysis was carried out with a Shimadzu liquid chro-
matography system and autosampler (Shimadzu, Kyoto, Japan), an 
analytical chromatographic column (Phenomenex Kinetex EVO C18 
2.6 μm 50*2.1 mm), and a triple quadripole mass spectrometer system 
(API 3000, Sciex, Framingham, MA). Analyst software was used for LC- 
MS/MS instrument control, data acquisition and chromatogram peak 
integration. Watson® LIMS software (Thermo Electron, Philadelphia, 
PA) was used for sample and data management including regression, 
concentration calculations and statistics. All concentrations were gen-
erated from runs that fulfilled the predefined acceptance criteria and 
sample assay was completed within the time period for which stability 
data were available. Using LC-MS/MS, endogenous and administered 
citric acid, cholesterol, and DPPC cannot be discriminated. However, as 
the basal levels of these two components are generally stable, any in-
crease following the administration of the liposomes can be related to 
the therapeutic intervention. 
Table 1 
Treatment groups in the Göttingen minipig study.       
Group Treatment identification Citric acid/lipids (mg/mL) Dose (mg/kg) Number of animals  
1 Control – 0 10 (5 males, 5 females including 2 recovery animals)a 
2 LSPD medium dose Citric acid: 3.54 
Lipids: 6.49 
Citric acid: 106 
Lipids: 195 
7 (4 males, 3 females) 
3 LSPD high dose Citric acid: 4.66 
Lipids: 10.6 
Citric acid: 140 
Lipids: 318 
8 (4 males, 4 females including 2 recovery animals) 
a 2 animals (1 male and 1 female) did not complete the study due to catheter malfunction.  
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2.2.5.2. Pharmacokinetic calculations (citric acid, DPPC and 
cholesterol). Individual plasma and dialysate concentration versus time 
profiles of citric acid, DPPC and cholesterol were subjected to 
pharmacokinetic (PK) analysis using the software Phoenix WinNonlin 
Version 6.3 (Pharsight Corporation, Mountain View, CA). A non- 
compartmental analysis using WinNonlin model 200 (extravascular 
bolus dose model) was performed. When the plasma or dialysate 
concentrations were below the LLOQ, the data point was entered as 
the value of the LLOQ (i.e., 0.500 μg/mL for DPPC and 10.0 μg/mL for 
cholesterol and citric acid). 
2.2.5.3. Plasma concentration profiles. The following PK parameters 
were determined from the plasma concentration profiles of citric 
acid, DPPC and cholesterol: the maximum plasma concentration 
(Cmax) and the time when it occurred (tmax) were estimated by visual 
inspection of the data. The area under the plasma concentrations vs. 
time curve from time zero to 3 h, 24 h and time at last measurable 
concentration Clast post-dose (AUC0–3, AUC0–24 and AUC0-t, 
respectively) were calculated according to the linear/log trapezoidal 
method. The area under the curve from time zero to infinity (AUCinf) 
was calculated with Eq. (1): 
= +AUC AUC C /inf 0 t last z (1) 
where λz is the elimination rate constant determined by linear 
regression using at least 3 data points from the terminal phase of the 
curve; an R2 above 0.80 was deemed acceptable. The half-life t½ was 
calculated with Eq. (2): 
=t ln2/½ z (2)  
The apparent systemic clearance (CL/F) and apparent volume of 
distribution (Vz/F) were calculated according to Eqs. (3) and (4), re-
spectively: 
=CL/F Dose/AUCinf (3)  
= ×V /F Dose/( AUC )z z inf (4)  
Furthermore, the accumulation ratio (RA) following repeated ad-
ministrations was calculated using Eq. (5): 
=R AUC /AUCA day10 day1 (5) 
using either AUC0-t or AUC0–24. 
2.2.5.4. Dialysate concentration profiles. The PK parameters were 
determined from the dialysate concentration profiles of citric acid, 
DPPC and cholesterol analogously. The area under the dialysate 
concentration vs. time curve from time zero to 3 h post-dose (AUC0–3) 
was calculated according to the linear/log trapezoidal method. 
Furthermore, the amount of each compound recovered at 3 h post- 
dose was calculated using the concentration at 3 h post-dose and the 
volume recovered at the end of the dialysis session; the corresponding 
%dose recovered at 3 h post-dose was calculated using Eq. (6): 
= ×%Dose recovered Amount recovered 100/Total dose administered
(6)  
2.2.6. Efficacy 
2.2.6.1. Blood and dialysate samples. On the first (day 1) and last days 
(day 10) of repeated treatments, blood samples of approximately 3 mL 
were drawn from the jugular vein/bijugular trunk of Göttingen 
minipigs. The samples were collected pre-dose as well as 1, 2, 3 
(sampled before start of drainage) and 5 h after start of treatment 
into vacutainers containing K3EDTA as anticoagulant. The vacutainer 
was placed in ice water until centrifugation (10 min, 1270 x g, 4 °C). 
Each plasma sample was then transferred to Nunc cryotubes and 
ammonia was analyzed within 2 h after sample collection. 
At days 1 and 10, dialysate samples of 3 mL were collected from the 
LSPD fluid before administration as well as from the dialysate as 
described above in the PK Section. Within 1 h after collection, samples 
were stored frozen at −18 °C or below pending analysis. 
2.2.6.2. Ammonia analysis. The concentration of ammonia in collected 
plasma, LSPD and dialysate samples was measured by an enzymatic 
method using Cobas 6000 analyzer (Hoffmann-La Roche, Basel, 
Switzerland) with the ammonia kit from Hoffmann-La Roche 
(catalogue number 20766682322). The measurement of ammonia in 
plasma was as described in the kit instructions. The method was 
adapted and qualified for ammonia analysis in medium and high dose 
LSPD. 
The measurement of ammonia in plasma samples was performed 
within 2 h from blood collection for most of the samples. The results 
obtained for the few samples analyzed outside this time frame, did not 
deviate from the other results. 
The LSPD and dialysate samples were pretreated as follows before 
measurements on the Cobas 6000 analyzer. The solutions were added 
15% Triton X100 at a 2:1 volume ratio yielding a Triton X100 con-
centration of 5%. The samples were then incubated at room tempera-
ture for 1 h and placed in an ultrasonic bath for 10 min. A series of 
dilutions of ammonia in phosphate-buffered saline were prepared and 
the measured mean concentration of ammonia were used to calibrate 
the ammonia concentration in LSPD (medium and high doses) and in 
the dialysate samples. 
2.2.6.3. Calculations. Individual plasma and dialysate ammonia 
concentration vs. time profiles were subjected to non-compartmental 
analysis similar to the PK analysis. When the plasma, LSPD or dialysate 
concentration of ammonia was below the LLOD (6.4 μM for plasma, 
36.6 μM for medium dose LSPD and 40.8 μM for high dose LSPD), the 
data point was entered as zero for the calculations. Cmax, Tmax and 
AUC0–3 were estimated as explained under the PK section. 
Ammonia clearance in the peritoneal fluid (CL,NH3) was calculated 
as follows (Eq. (7)): 
= ×CL, C , Volume LSPD recovered/plasma ammonia AUCNH3 NH3 dial,3h 0–3
(7)  
Where CNH3,dial,3h is the ammonia concentration in the dialysate 
measured at 3 h. 
2.2.7. Toxicological testing 
2.2.7.1. Clinical signs. All visible signs of ill health and any behavioral 
changes of the Göttingen minipigs were recorded daily prior to dosing 
and during the study conduct. In addition, a dose related observation 
was performed 1 h ( ± 15 min) after end of dosing. Any deviation from 
normal was recorded. It was also recorded if any Göttingen minipig 
showed mortality/morbidity at the start and end of the day. 
2.2.7.2. Body weight. Starting on arrival, the animals were weighed 
twice weekly during the pre-treatment period. During the dosing and 
recovery period, the animals were weighed daily in the morning under 
fasted conditions and this value was used for the calculation of the daily 
dose. Moreover, the animals were weighed at necropsy. 
2.2.7.3. Electrocardiography (ECG). Before start of treatment and on a 
single day during the treatment period (day 5), the animals were 
subjected to electrocardiographic examination using Marquette MAC 
3500 (GE Healthcare, Chicago, IL). Furthermore, the recovery animals 
were re-examined on a single day during the recovery period (days 22/ 
23). The electrocardiographic recordings were performed 
approximately 1 and 6 h ( ± 30 min) after end of dosing. Before start 
of treatment and during the recovery period, recordings were 
performed at approximately the same time of days as those done 
during the dosing period. The electrocardiograms were recorded with 
the animal placed in a sling. A 6‑lead system (axial leads) consisting of 
the bipolar leads I, II and III, and of the augmented leads aVL, aVR and 
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aVF was used. The speed of the paper was 50 mm/s and amplification 
1 mV/cm. The minimum recording period was approximately 15 s. 
The P-wave duration, PR, QRS, QT, and RR intervals were measured 
from preferably lead II. The result for PR, QRS and QT were the average 
of the measurements of three subsequent beats, whereas the result for 
RR was the average of ten subsequent beats. The heart rate (beats per 
min) was calculated on basis of the recordings. To compare QT mea-
surements at different heart rates, a rate correction of the QT interval 
was calculated using the Fridericia method (QTcF) [19]. 
2.2.7.4. Ophthalmoscopy. Before start of treatment and on a single day 
during the treatment period (day 9), ophthalmoscopy was performed on 
all animals. Furthermore, the recovery animals were reexamined on a 
single day during the recovery period (days 22/23). After application of 
tropicamide 1% solution (Mydriacyl, Alcon, Geneva, Switzerland), both 
eyes were examined with an indirect ophthalmoscope and a portable 
slit-lamp microscope. 
2.2.7.5. Clinical pathology. Before start of treatment and on a single day 
during the treatment period (day 9), blood samples were taken from all 
animals. Furthermore, blood samples were taken from all recovery 
animals on a single day during the recovery period (days 23/24). The 
animals were fasted overnight before blood samples were taken but 
water was available. Blood samples were drawn from the jugular vein/ 
bijugular trunk. 
2.2.7.6. Hematology and coagulation. For hematology, at least 2.5 mL 
K3EDTA -stabilized blood was taken. 
For the coagulation tests, 1.8 mL citrate stabilized blood was taken. 
The following parameters were investigated: hemoglobin, red blood cell 
count, reticulocyte count, hematocrit, mean cell volume, mean cell 
hemoglobin, mean cell hemoglobin concentration, white blood cell 
count, differential leucocyte count (neutrophils, lymphocytes, eosino-
phils, basophils, monocytes), platelet count (ABX Pentra DX120SPS, 
Horiba, Kyoto, Japan), activated partial thromboplastin time with 
synthetic phospholipids, prothrombin time, fibrinogen (IL Test™ / ACL 
Top™, Instrumentation Laboratory, Bedford, MA). 
2.2.7.7. Clinical chemistry. Approximately 3 mL of blood was taken for 
clinical chemistry in plain glass tubes for serum. The following 
parameters were investigated: alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, bilirubin (total), gamma- 
glutamyl transferase, cholesterol, triglycerides, carbamide (urea), 
creatinine, glucose, sodium, potassium, calcium, magnesium, 
inorganic phosphorous, chloride, protein (total), albumin (Cobas 6000). 
2.2.7.8. Urinalysis. Before start of treatment, urine was collected from 
all animals. At termination of treatment, urine was collected from all 
animals (except for the recovery animals) in connection with the 
necropsy. Furthermore, urine samples were taken from all recovery 
animals in connection with the necropsy. During urine sampling (before 
start of treatment), the animals were housed individually in metal cages 
with a floor area of at least 0.72 m2. Urine samples were collected 
overnight from the stainless-steel tray under the cage. No afternoon 
meal was given, and only water was available during the sampling 
period. The volumes of the urine samples were recorded and aliquots of 
up to 10 mL were saved for the analyses. 
The following urine parameters were investigated: volume, color 
(visual inspection), specific gravity, pH, protein, leucocytes, nitrite, 
blood, glucose, ketones, bilirubin, urobilinogen (Siemens Multistix 10 
SG, Clinitek Advantus Analyzer, Siemens Healthineers, Erlangen, 
Germany). 
2.2.7.9. Necropsy. At necropsy, macroscopic examination was 
performed by observing the appearance of the organs and tissues in 
situ. Any macroscopic change was recorded with details of the location, 
color, shape and size in Provantis® (version 9.3.0.0, Instem, Stone, UK). 
2.2.7.10. Organs and tissues. Either whole organs or selected samples of 
the indicated organs and tissues were subjected to the procedure below. 
Weights were recorded in Provantis®. 
Paired organs were weighed together. The relative organ weights 
(i.e., as a percentage of the body weight and as a percentage of the brain 
weight) were calculated for each animal. 
All tissues were initially fixed in phosphate buffered neutral 4% 
formaldehyde except for the eyes and testes (Modified Davidson's 
fixative). The lungs were infused with fixative at necropsy. 
2.2.7.11. Microscopic examination. Samples from all animals were 
trimmed and representative specimens were taken for histological 
processing. The specimens were embedded in paraffin and cut at a 
nominal thickness of approximately 5 μm, stained with hematoxylin 
and eosin, and examined under a light microscope. All organs and 
tissues were examined microscopically. Histological alterations were 
graded on a 5-level scale (minimal, mild, moderate, marked, and 
severe). 
2.2.8. Ammonia infusion study 
In this part of the study, the safety and efficacy of LSPD was in-
vestigated in an artificially induced hyperammonemic pig model. 
Domestic pigs (9–14 kg, n = 2 per group) were anesthetized (sevo-
flurane inhalation), endotracheally intubated, kept warm (37.5 °C – 
38.5 °C), and thoroughly monitored throughout the study (ECG, in- and 
expired gas composition, intra-arterial blood pressure, heart and re-
spiratory rates, eye reflexes). Buprenorphine (0.02 mg/kg intravenous) 
and meloxicam (0.4 mg/kg intramuscular) were administered for pre- 
emptive analgesia. A pediatric PD multi-perforated catheter (8.5 
French, Cook Medical, Bloomington, IN) was inserted in the lower ab-
dominal quadrant of the anesthetized pigs by minimal sterile surgery. 
After surgery, the pigs were continuously infused for 4 h with an am-
monium chloride solution at 1 mmol/kg/h (11.5 mL/kg/h) and their 
ammonium plasmatic levels were monitored (PocketChem BA PA-4140, 
Arkray, Japan) at allotted time points (baseline and at t = 0.25, 0.5, 
0.75, 1, 1.5, 2, 2.5, 3.5, 4 h). Pre-warmed (37 °C) LSPD or Physioneal® 
35 1.36% w/v were temporarily injected (40 mL/kg equivalent to 192 
and 234 mg/kg citric acid and lipids, respectively) in the peritoneal 
cavity for 3.5-h dwell periods. At the end of the experiment, the dia-
lysate was drained out of the peritoneal cavity by gravity and soft 
suction. Subsequently, the pigs were anesthetized and euthanized by 
intravenous administration of pentobarbital (80 mg/kg). 
2.3. Statistics 
The statistical calculations were carried out by SigmaPlot (version 
13.0) and Microsoft Excel 2016 (linear regression analysis). Three or 
more groups were compared using one-way ANOVA and Tukey's post- 
hoc test. Two groups were compared using Student's t-test. A p-value 
of < 0.05 was deemed statistically significant. 
2.4. Safety margin of FIH dose and anticipated citric acid exposure in 
patients 
Due to the limited exposure to lipids, the safety margin of the LSPD 
dose selected for the FIH study was estimated for citric acid using a PK- 
guided approach. The first step consisted in calculating the human 
equivalent dose (HED) as follows (Eq. (8)): 
= ×HED (CL /F) AUCpatients inf,day10,NOAEL (8)  
Where CLpatients represents the clearance of citric acid in cirrhotic 
and non-cirrhotic patients already published in the literature (i.e., 265 
and 592 mL/h/kg, respectively) [20]; F is the bioavailability assumed 
to be 1 (most conservative estimate giving the highest exposure); 
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AUCinf,day10,NOAEL is the area under the curve from 0 to infinity at day 
10 following the No Observed Adverse Effect Level (NOAEL) as defined 
in this repeated dose toxicity study. The calculation of AUCinf is de-
scribed under the PK section. 
In a second step, the safety margin of the starting dose of LSPD in 
humans was calculated as follows (Eq. (9)): 
=Safety margin HED/FIH LSPD starting dose (9)  
Finally, the exposure to citric acid anticipated in patients in the FIH 
trial was estimated using the starting dose of LSPD and CLpatients (ob-
tained from the literature) according to Eq. (8) [20]. 
3. Results and discussion 
3.1. Pharmacokinetics 
3.1.1. Pharmacokinetics in plasma 
During the extemporaneous preparation of LSPD, liposomes are 
loaded with citric acid using an osmotic shock with an encapsulation 
efficiency of ~12% [13]; substantial amounts of deprotonated citrate 
remain in the external phase and contribute to the osmolarity of the 
formulation. As shown in our previous work, encapsulated citric acid is 
the fuel for ammonia capture capacity of LSPD fluids. Moreover, Braide 
et al., reported that citrate supplementation of a PD fluid improves 
ultrafiltration and clearance of small solutes in single dwells although 
the exact mechanism of action remains unknown [21]. Consequently, 
the PK of citric acid following LSPD treatment was assessed. Upon 
single and multiple administrations of the medium and high dose LSPD 
fluids, maximum citric acid plasma concentrations were reached ap-
proximately 1 h post-dose (Fig. 2A, Supplementary Fig. S1A, Table 2). 
The high dose led to higher plasmatic levels than the medium dose both 
on days 1 and 10, most likely due to the absorption of unencapsulated 
citric acid from the peritoneum. Mean plasma concentrations subse-
quently declined in a biphasic manner and returned to pre-dose levels 
between 7 and 12 h post-dose similarly for both doses and treatment 
days. The extent of exposure to citric acid increased in a dose-depen-
dent manner as the Cmax increased proportionally with the dose on days 
1 and 10 (p  <  0.01); the increase in AUC0–24 reached significance on 
day 1 and showed a trend towards significance on day 10 (p = 0.061, 
Supplementary Table S1). For males and females combined, the mean 
Cmax was approximately 109 vs. 77.0 μg/mL and the mean AUC0–24 
ranged between 654 and 706 vs. 473–570 μg·h/mL for high vs. medium 
dose LSPD (Table 2). The mean half-life (t1/2) of citric acid was 2–3 h, 
and similarly to CL/F and Vz/F (approximately 200 mL/h/kg and 
700–800 mL/kg, respectively), it was not significantly different be-
tween the two doses on the same treatment day (Supplementary Table 
S1). The plasma Cmax and AUC0–24 were considerably lower than the 
reported safe maximum values in critically ill cirrhotic patients 
(307 μg/mL and 903 μg·h/mL [20]). Importantly, there was no systemic 
accumulation of citric acid in minipigs following daily intraperitoneal 
infusions of medium and high dose LSPD fluids over 10 days (Supple-
mentary Table S2). The plasma PK profile of citric acid was comparable 
in males and females as no significant gender differences in the plasma 
concentration curves were observed within the same dose (Supple-
mentary Fig. S2, Supplementary Table S3). Since the risk to suffer from 
HE affects both genders equally [22], the absence of a gender effect 
based on individual PK data provides assurance that both female and 
male patients meeting the inclusion criteria could be safely included in 
the first clinical trial. 
The linear PK of citric acid following intraperitoneal administration 
of LSPD is an important property to accurately select the starting dose 
in patients. This is especially relevant since the European Medicine 
Agency recently revised its guideline on FIH trials [23]. While the 
previous version of the guideline focused on the emergence of non- 
clinical adverse events for estimating safe doses in FIH studies, the 
current revision advocates to consider the profile of the dose/exposure- 
response curves within the anticipated therapeutic range (e.g., steep-
ness, plateau of the curve) and a clear limit to exposure must be pro-
vided in the protocol. 
Intraperitoneally applied liposomes enter the lymphatics at the 
diaphragm and are drained into the circulatory system at the jugu-
lar–subclavian junction [24]. After a single administration of LSPD in 
minipigs, the systemic absorption and elimination of DPPC were slow; 
DPPC plasma concentrations remained above baseline levels at the end 
of the dosing interval (Fig. 2B, Supplementary Fig. S1B). Therefore, the 
terminal elimination phase of DPPC could not be adequately char-
acterized on day 1 and all λz-related PK parameters (i.e., AUCinf, CL/F 
and Vz/F) should be interpreted with caution (Table 3). On day 10, 
DPPC plasma concentrations declined in a biphasic manner and re-
turned to pre-dose levels after 16 to 24 h post-dose in both treatment 
groups. The rate and extent of exposure to DPPC in minipigs as well as 
systemic elimination were comparable across doses as no significant 
differences in Cmax, AUC0–24, tmax, t1/2, CL/F, or Vz/F were observed 
between the two doses on the same treatment day (Supplementary 
Table S4). The mean Cmax ranged between 112 and 130 μg/mL on day 1 
and 72.8–105 μg/mL on day 10. The mean AUC0–24 ranged between 
1905 and 1959 μg·h/mL and 798–1136 μg·h/mL on day 1 and day 10, 
respectively (Table 3). On day 10, the mean half-life in both groups was 
between 11.3 and 15.4 h. The DPPC plasma concentration curves were 
not statistically different within a given dose between male and female 
animals (Supplementary Fig. S3, Supplementary Table S5). Further-
more, following multiple intraperitoneal administrations of medium 
and high dose LSPD q.d., there was no systemic accumulation of DPPC 
in minipigs (Supplementary Table S2). 
Interestingly, the overall extent of exposure appeared to decrease on 
day 10 compared to day 1; mean Cmax values were comparable 
(Table 3). The difference in the DPPC AUC0–24 between days 1 and 10 
was only significant in the medium dose group (Supplementary Table 
S4). This trend towards lower systemic exposure following multiple 
dosing might be related to the accelerated blood clearance phenom-
enon. The later has been reported for PEGylated liposomes upon re-
peated administrations in several species (rats, rhesus monkeys, mice, 
minipigs, dogs) and is likely related to the opsonization of these vesicles 
by anti-PEG immunoglobulin M antibodies [25–29]. In general, the 
extent of exposure to DPPC inversely correlated with the amount of 
DPPC recovered at the end of intraperitoneal treatments with LSPD 
(Fig. 3A), which in turn depended on the volume of fluid drained from 
the abdominal cavity (Fig. 3B). 
To estimate the maximum recoverable DPPC dose, the recovered 
DPPC was compared to the recovered volume of LSPD fluid (Fig. 3B). 
Based on a linear regression, it was estimated that draining out 100% of 
LSPD would remove approximately 77% of the total lipids adminis-
tered, implying that about 23% of the dose is absorbed during the dwell 
time of 3 h. Analogous calculations for cholesterol yielded a similarly 
low absorption for cholesterol (approx. 21%) assuming full LSPD re-
moval (Supplementary Fig. S4). Therefore, most liposomes remain 
confined in the peritoneal space during the dwell time. In contrast, 
draining the entire LSPD volume would theoretically remove about 
33% of citric acid (Supplementary Fig. S5), indicating that about two 
thirds the citric acid dose was absorbed in the systemic circulation and 
subsequently eliminated. We hypothesize that in the clinical practice a 
shorter dwell time (e.g., 2 h) and an efficient drainage of LSPD via the 
introduction of a washing step may significantly reduce the overall 
exposure to liposomes in the systemic circulation. 
The rate (Cmax) and extent of exposure (AUC) to cholesterol in 
minipigs were similar following repeated intraperitoneal infusions of 
medium and high dose LSPD (Supplementary Table S6, no statistically 
significant differences). In fact, cholesterol concentrations following 
both doses remained around baseline levels and λz-related PK para-
meters could not be calculated. The apparent differences in observed 
absorption between cholesterol and DPPC could be related to the lower 
amount of cholesterol in the formulation and higher endogenous levels. 
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Following multiple intraperitoneal infusions of medium and high doses 
LSPD daily over 10 days, there was no plasma accumulation of cho-
lesterol (Supplementary Table S2). 
3.1.2. Pharmacokinetics in dialysate 
Significant differences between medium and high dose LSPD were 
observed for Cmax and AUC0–3 of dialysate citric acid and DPPC (Fig. 2C 
and D, Table 4, Supplementary Tables S7 and S8). Citric acid con-
centrations in the peritoneal fluid declined more rapidly than DPPC 
indicating the more rapid absorption in the systemic circulation. Indeed 
on days 1 and 10, only 7% to 37% of the dose of citric acid was re-
covered in the dialysate at the end of the PD session whereas the per-
centage of recovered DPPC in the dialysate varied between 21% and 
96% and correlated well with the volume of dialysate recovered at the 
end of the PD session (Supplementary Table S9). The low dialysate 
recovery and hence the higher exposure to lipids achieved in certain 
cases was likely related to the omentum wrapping of the catheter or to 
the localization of the catheter inside the peritoneal space, which 
probably impeded optimal drainage. In patients, however, the catheter 
would not be implanted surgically. A catheter for paracentesis would be 
used and it is expected that the recovery of the dialysate would improve 
and be less variable. The PK profile of citric acid and DPPC in the 
peritoneal space was linear both on days 1 and 10 at the medium and 
high LSPD doses. There seemed to be no accumulation in the peritoneal 
cavity on day 10 (Supplementary Table S2). Furthermore, the dialysate 
citric acid and DPPC concentrations of male and female minipigs were 
not significantly different (Supplementary Figs. S6 and S7). 
3.2. Efficacy 
Following intraperitoneal administration, ammonia Cmax and 
AUC0–3 were significantly higher in the dialysate of minipigs in the 
medium and high dose LSPD groups than the control group on both 
treatment days (Table 5, Supplementary Table S10). In addition, these 
two PK parameters dialysate ammonia curves were significantly higher 
for the high dose than the medium dose (Fig. 4A and B). Therefore, 
there was a citric acid dose-dependent increase in ammonia capture 
between the two groups of LSPD-treated minipigs. This indicates that 
Fig. 2. Mean PK profile of citric acid and DPPC in plasma and dialysate of LSPD-treated minipigs following single (day 1) and multiple doses (day 10). Plasma citric 
acid concentrations over time after LSPD administration (A). Plasma DPPC concentrations over time after LSPD administration (B). Peritoneal citric acid con-
centrations over time after LSPD administration (C). Peritoneal DPPC concentrations over time after LSPD administration (D). On both treatment days, dialysate 
concentrations were significantly higher for high dose LSPD than medium dose for citric acid up to 2 h post-dose (p  <  0.01, C) and for DPPC for all investigated time 
points (p  <  0.001, D). Mean + SD (n = 7–8). 
Table 2 
Mean PK parameters of plasma citric acid (n = 7–8). Statistically significant differences are reported in Supplementary Table S1.             
Dose Day Cmax (μg/mL) tma× (h) t1/2 (h) AUC0–3 (μg·h/mL) AUC0–24 (μg·h/mL) AUCinf
a (μg·h/mL) AUCext (%) CL/F
1 (mL/h/kg) Vz/F
1 (mL/kg)  
Medium 1 76.6 0.786 2.32 179 473 508 7.07 232 785 
Medium 10 77.1 0.786 2.98 182 570 639 10.5 185 787 
High 1 110 0.875 2.04 251 654 697 6.61 226 683 
High 10 108 0.625 2.58 235 706 782 9.52 200 753 
a Based on AUC0–24.  
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the extraction of ammonia in the dialysate could be well controlled by 
the citric acid dose in LSPD fluids. A similar dose effect of LSPD fluid 
citric acid on dialysate ammonia concentration was observed in healthy 
rats [13]. However, in contrast to healthy rats, where a linear increase 
in ammonia uptake was seen up to 4 h [13], the ammonia sequestration 
leveled off after 1 h in minipigs. Importantly, dialysate ammonia Cmax 
and AUC0–3 were not significantly different on the first and tenth day of 
daily LSPD infusions. Furthermore, there were no gender differences in 
the DPPC dialysate ammonia concentration curves within the same 
dose and treatment day. 
No changes in plasma ammonia concentrations were observed upon 
LSPD administration (Fig. 4C). This result was expected as in healthy 
animals ammonia levels are low due to an efficient hepatic clearance 
[30,31]. We previously reported in bile duct ligated rats (a liver disease 
model) that LSPD was indeed efficient to reduce hyperammonemia and 
associated HE [13]. Similarly, a recent study found that an ammonia- 
sequestering treatment efficiently decreased systemic ammonia levels 
in hyperammonemic rats but failed to show effects in healthy control 
rats, potentially due to difficulties in reliably quantifying low ammonia 
concentrations and/or because of acid-base homeostasis-regulating 
ammoniagenic pathways activated in response to hypoammonemia 
[16,32–35]. To confirm that LSPD would remove excessive plasma 
ammonia in a large animal model, we conducted a pilot experiment in 
which ammonia was continuously infused in domestic pigs to reach a 
hyperammonemic state of approximately 200 μM. In this setup, we 
showed that LSPD enhanced the elimination of ammonia, reducing the 
plasmatic concentrations by 30% within 3 h from infusion onset, 
compared to a 10% increase observed in the control group treated with 
Physioneal® 35 1.36% w/v (Supplementary Fig. S8). These preliminary 
outcomes support the initial proof of concept in rodents and encourage 
the future clinical development of LSPD as a first-line support for acute 
and life-threatening hyperammonemia in urea cycle defects and related 
liver deficiencies. In pediatric patients, the treatment of acute hyper-
ammonemia is currently challenging because of the delayed onset of 
action of metabolic treatments and the invasiveness of hemodialysis 
[1,3]. Therefore, LSPD as a rapidly acting and mildly invasive treatment 
modality promises to improve the overall prognosis of these patients. 
Mean ammonia peritoneal fluid clearance (CL,NH3) measured in mini-
pigs ranged between 5.33 and 11.5 mL/min (Supplementary Table 11) 
following single and multiple doses LSPD. This result was in the same 
Table 3 
Mean PK parameters of plasma DPPC (n = 4–8). Statistically significant differences are reported in Supplementary Table S4.             
Dose Day Cmax (μg/mL) tma× (h) t1/2 (h) AUC0–3 (μg·h/mL) AUC0–24 (μg·h/mL) AUCinf (μg·h/mL) AUCext (%) CL/F (mL/h/kg) Vz/F (mL/kg)  
Medium 1 112 9.28 16.7 91.5 1905 3375 42.9 59.6 1410 
Medium 10 72.8 4.67 15.4 76.2 798 1530 12.4 135 2910 
High 1 130 11.6 15.8 103 1959 2755 44.5 142 3110 
High 10 105 7.38 11.3 108 1136 1405 10.3 304 3994    
Fig. 3. DPPC exposure vs. LSPD recovery in minipigs. DPPC AUC0–24 in plasma vs. recovered DPPC doses (R
2 = 0.7478, A). Relationship between recovered amount 
of DPPC (expressed as % of the dose administered) and recovered volume of LSPD (R2 = 0.7523, B). Data presented from medium dose LSPD on day 1. 
Table 4 
Mean PK parameters of dialysate citric acid and DPPC (n = 7–8). Statistically significant differences are reported in Supplementary Tables S7 and S8.        
Dose Day Citric acid DPPC 
Cmax (μg/mL) AUC0–3 (μg·h/mL) Cmax (μg/mL) AUC0–3 (μg·h/mL)  
Medium 1 3641 5372 6197 15,070 
Medium 10 3636 5244 5880 15,611 
High 1 4715 6963 10,813 25,128 
High 10 4598 6679 10,988 27,230    
Table 5 
PK parameters of peritoneal fluid ammonia (mean  ±  SD; n = 6–8). 
Statistically significant differences are reported in Supplementary Table S10.       
Group Cmax (μM) AUC0–3 (μmol·h/mL) 
Day 1 Day 10 Day 1 Day 10  
Control 67.5  ±  13.9 57.5  ±  12.5 15.6  ±  3.41 13.0  ±  1.71 
Medium dose 251  ±  65.3 199  ±  49.0 53.1  ±  13.8 45.3  ±  12.0 
High dose 344  ±  40.6 323  ±  76.2 79.0  ±  11.8 79.5  ±  19.5 
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range compared to other dialysis modalities used as standard of care in 
pediatric patients with acute hyperammonemia for which ammonia 
clearance varied between 2.5 and 21.5 mL/min [36]. It is therefore 
anticipated that the performance of LSPD in clearing ammonia can at 
least reach that of hemodialysis. This is yet to be confirmed in future 
clinical trials. 
3.3. Toxicology 
The toxicity of LSPD was assessed on minipigs mainly because 
anaphylactoid-like reactions, a serious adverse event for colloidal for-
mulations, are not reported in rodents [37] and due to the complexity 
of performing repeated peritoneal administrations in small size animals. 
The parameters evaluated in the study included clinical signs, body 
weight, food consumption, ophthalmoscopy, clinical pathology (blood 
and urine) and electrocardiography. At necropsy, a full pathological 
evaluation including organ weight and histopathological examination 
of selected tissues was performed. 
The medium and high LSPD doses were well-tolerated in both males 
and females. No LSPD-related changes in food consumption, clinical 
pathology, and organ weights were found. All animals had a normal 
body weight gain throughout the study except for the male medium 
dose group, which had a significantly lower body weight gain from Day 
1 to Day 12 (Supplementary Tables S12 and S13). This finding was 
judged of no toxicological importance as it was only observed in males 
from a single treatment group. Furthermore, there were no changes in 
coagulation parameters and most biochemical and blood parameters 
(Supplementary Tables S14-S17). The lack of effect of citrate on blood 
coagulation and clinical chemistry parameters is an important finding 
as the latter is known to chelate ionized calcium and may be associated 
to bleeding, hypocalcemia and metabolic acidosis, which would re-
present adverse effects of special interest for LSPD [38]. 
Treatment with LSPD had no important influence on the electro-
cardiography (Supplementary Tables S18 and S19). A significant de-
crease in heart rate and a significant increase in the RR interval was 
observed in females on day 5 at 1 h post-high dose LSPD. At 6 h post- 
dose, a significant increase in QT was observed in the same group but 
the corrected QTcF showed no significant changes. These observations 
were judged of no toxicological importance as no clear trend was ob-
served across the two timepoints. Overall, based on cardiovascular 
parameters, white blood cells and body temperature, no anaphylactoid- 
like reactions were reported in minipigs treated with LSPD in ac-
cordance with our previous study [13]. 
At macroscopic examination, adhesions extending from the ca-
theter/implantation site to various tissues and organs were recorded in 
one or more animals in all investigated groups. Other macroscopic 
findings most likely related to catheter implantation were a grey-white 
focus on the spleen in one animal, pink discoloration of the peritoneum 
and red discoloration of the serosa of the cecum in single or a few 
animals. The tissue of the thymus of several animals treated with the 
liposomal formulation were found to be firm to the touch. 
The histopathologic analysis of the spleen, liver, and kidney did not 
show treatment-related toxicity (Supplementary Table S20). 
Microscopic findings considered to be related to the liposomal for-
mulation included minimal to strong presence of vacuolated macro-
phages (mainly microvesicular vacuolation) in lymph nodes of the 
LSPD-treated animals. Furthermore, a minimal to mild infiltration of 
similar vacuolated macrophages was seen in various tissues of some 
LSPD-treated animals irrespective of the dose. Vacuolated macrophages 
were only seen in a few tissues of one recovery animal (male) receiving 
LSPD high dose, indicating on-going recovery. These findings were 
expected as macrophages are involved in the clearance of liposomes 
[39–41]. A recent study identified that intraperitoneally applied lipo-
somes mainly entered the lymphatics at the diaphragm and were 
drained via the thoracic lymph to the jugular–subclavian junction, ac-
cumulating preferentially in mediastinal lymph nodes [24]. This report 
is in accordance with our finding that the firm lymph nodes, which 
were subsequently sampled and showed vacuolated macrophages, were 
adjacent to the thymic tissue, while no histopathologic findings were 
made in the mesenteric lymph nodes of the treated animals 
Fig. 4. In vivo ammonia extraction by LSPD in minipigs. Ammonia concentra-
tions in dialysate fluid containing ascending doses of citric acid during 3 h of PD 
on days 1 (A) and 10 (B). Plasma ammonia concentrations during and after 3 h 
of PD on days 1 and 10 (C). Dialysate ammonia concentrations were sig-
nificantly higher for medium and high dose LSPD than control PD starting from 
1 h post-dose (p  <  0.01, A and B). No statistically significant differences in 
plasma ammonia were observed for LSPD over control PD (C). Mean + SD 
(n = 6–8). 
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(Supplementary Table S20). Furthermore, the aforementioned study 
reported that liposomes with a high degree of PEGylation (6 mol% of 
mPEG-DSPE) are less prone to accumulate in lymph nodes compared 
with non-PEGylated liposomes. 
Microscopic findings considered to be related to the catheter im-
plantation procedure and peritoneal administration of the liposomal or 
the control formulations included an inflammatory response around the 
catheter implantation sites, in the omentum and peritoneal samples, 
and in the peritoneal/serosal surfaces of several abdominal organs (e.g., 
liver, pancreas, spleen) as well as in additional tissues (e.g., muscle 
tissue) adjacent to collected tissues and organs. Other microscopic 
findings observed in the study animals were considered incidental and/ 
or within the range of expected findings in Göttingen minipigs of this 
age. 
3.4. Rationale for dose selection and anticipated exposure to citric acid/ 
lipids in humans 
For all groups of minipigs, the 10-day duration of the repeated dose 
toxicity covered more than the maximum time during which clinical 
exposure is anticipated in liver decompensated patients. Overall, both 
formulations were safe. High dose LSPD was defined as the NOAEL even 
though a maximum tolerated dose has not been reached. Nevertheless, 
considering the lack of supportive data on the permeability of the 
peritoneal membrane in liver impaired patients, and the possibility of 
liposomes' associated CARPA reactions, the medium dose LSPD 
(3.54 mg/mL citric acid / 6.49 mg/mL lipids) given at 15 mL/kg was 
selected as a starting dose in patients, which represents a total dose of 
53.1 mg/kg citric acid (Table 6) which is considerably lower than the 
safe citric acid dose in critically ill patients (192 mg/kg [20]). Based on 
a PK-guided approach, a corresponding HED of 207–463 mg/kg was 
calculated according to citric acid clearance in cirrhotic and non-cir-
rhotic patients [20]. Considering that the safety profile of citric acid is 
already well known, the resulting safety margin above 3, gives enough 
confidence that the first dose of LSPD should not trigger serious adverse 
reactions in patients. Even though no effects on hematology or clinical 
chemistry were found during the toxicity program, these cannot be 
excluded in a clinical setting. Indeed, citrate is a well-known antic-
oagulant; a close monitoring of the coagulation parameters, ionized 
calcium levels, and acid-base status (blood gas analysis panel) is thus 
recommended to mitigate the risks associated to citrate during the FIH 
trial with LSPD, especially in liver impaired patients. 
The extent of exposure to citric acid (AUCinf) following in-
traperitoneal administration of LSPD at the starting dose, is expected to 
range between 89.7 and 200 μg·h/mL. This is lower than the value 
estimated from the literature data in critically ill cirrhotic patients 
(1008 μg·h/mL [20]) and minipigs at the NOAEL (782 μg·h/mL). The 
risks of citric acid related adverse events are therefore expected to be 
low also considering that citrate is the anticoagulant of choice used in 
patients undergoing extracorporeal dialysis [42,43]. Once LSPD's safety 
is confirmed in patients and preliminary PK and efficacy results are 
gathered, an appropriate dosing regimen (including dose level, length 
of dwell time, number of LSPD sessions per day) will be established 
prior to the phase II clinical proof of concept study. 
4. Conclusions 
Based on non-clinical proof of concept studies in bile duct ligated 
rats and in artificially induced-hyperammonemic domestic pigs, LSPD is 
a promising investigational treatment modality for hyperammonemia- 
associated disorders leading to brain edema or hepatic encephalopathy 
(e.g., metabolic disorders affecting the urea cycle, liver injuries). In this 
GLP study, we performed an in-depth analysis of the PK, ammonia 
uptake, and toxicological properties of peritoneally administered 
transmembrane pH-gradient liposomes in Göttingen minipigs. Once 
daily sessions with LSPD for ten days resulted in favorable PK with 
rapid absorption and elimination of citric acid and a low systemic ex-
posure to DPPC. Transmembrane pH-gradient liposomes concentrated 
ammonia in the peritoneal space to a higher extent than a liposome-free 
PD fluid. The study further confirmed the safety of LSPD in minipigs, 
one of the most sensitive species to colloidal formulations. The results 
of this work indicate a positive pharmacokinetic and toxicological 
profile for LSPD and support a clinical investigation in hyper-
ammonemic patients. 
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